Alvarez & Marsal Analyzes Life Sciences M&A Optimization

Management consulting firm Alvarez & Marsal has released an analysis on optimizing the investment lifecycle for mergers and acquisitions (M&A) within the Life Sciences sector. While M&A activity in the sector saw a downturn at the beginning of 2022 compared to a record year in 2021, the outlook for 2023 appears more promising.

Alvarez & Marsal notes that the Life Sciences sector, encompassing biopharma, medtech, and pharma services, experienced multi-year lows in both activity and deal value during 2022. However, improved conditions are anticipated for 2023, driven by available capital, the ongoing need for technological advancements, and potentially stabilizing valuations.

Major pharmaceutical companies, including Pfizer and Amgen, completed significant acquisitions in the latter half of 2022. Investment bank J.P. Morgan also launched a new life sciences private equity arm in November. Executing these deals effectively requires more than standard due diligence and integration support in today's market.

Alvarez & Marsal emphasizes the importance of maximizing value through mergers, divestitures, and spin-offs. The firm argues that improving operational performance across all aspects of the business is crucial. This involves developing a clear strategy, evaluating research and development (R&D) and product portfolios, enhancing sales and marketing functions, and optimizing operations using digital tools and analytics.

For private equity (PE) firms, Alvarez & Marsal recommends adopting an optimized strategy throughout the entire investment lifecycle, from acquisition to exit, to effectively enhance the value of the acquired company.